z-logo
open-access-imgOpen Access
A “A COMPARATIVE STUDY OF ASITAKADI CHURNA AND ALAMBUSADI CHUNA IN THE MANAGEMENT OF AMAVATA”
Author(s) -
Dr.PRIYANKA Kandikattiwar
Publication year - 2021
Publication title -
ayurline: international journal of research in indian medicine
Language(s) - English
Resource type - Journals
ISSN - 2456-4435
DOI - 10.52482/ayurline.v5i02.512
Subject(s) - medicine , clinical study , physical therapy
- INTRODUCTION: - Amavata is one of the challenging diseases for the physicians due to its chronic nature, difficulty, complications. Amavata is the prime disease which makes the person unfit for an independent life. In this study, Asitakadi Churna  and Alambusadi chuna are considered, as both the drugs possess Vata-Kaphahara and Amapachak properties. Here an attempt is made to compare the efficacy of Asitakadi Churna  and Alambusadi chuna in Amavata with the title “A Comparative study of Asitakadi Churna  and Alambusadi chuna in the management of Amavata” AIM & OBJECTIVE: - To compare effect of Alabushadi churna  and Asitakadi churna in Amavata. MATERIALS AND METHODS - The patients were selected from the OPD and IPD of concern institution. 60 patients of Amavata were randomly selected and divided into two groups of 30 patients each, and subjected to clinical trial. Group- A patients were treated with Asitakadi Churna  and Group-B patients were treated with Alambusadi chuna. The signs and symptoms were recorded on the preformed designed for the study and assessment was done on subjective and objective criteria and results were analyzed statistically. RESULT – In the present study, it is concluded that both Group A and Group B showed significance in decreasing shool, Shoth, gourava, and jadya. Asitakadi Churna  is equally effective as Alambusadi chuna in on  Amavata. CONCLUSION – The treatments were found to be statistically significant in reducing the signs and symptoms of the disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here